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BRAZIL'S SUPERIOR JUSTICE COURT
SHORTENS PIPELINE PATENT TERMS
WITH VIAGRA RULING
Vera Suarez*
IN National Institute of Industrial Property v. Pfizer Ltd., Brazil's Su-
perior Justice Court held that the patent term for pipeline patents-
created from Industrial Property Law No. 9,2791 (Law No. 9,279)-
begins from the priority date of the patent application and not the inter-
national filing date.2 The court considered this non-literal interpretation
of the law3 to best fit with the principles governing intellectual property
and the patent system in Brazil.4 The court's holding not only provided a
shorter patent term, but could possibly go against governing international
treaties, and has no doubt caused many pharmaceutical companies to lose
hundreds of millions of dollars within the Brazilian pharmaceutical mar-
ket.5 While the court's holding set precedent for other pipeline patent
term debates, shortening the patent term from June 7, 2011 to June 21,
2010 for the patent involving the Viagra technology, it should result in an
estimated $40 million loss to Pfizer alone.6
The Superior Justice Court's holding in Pfizer represented a final reso-
lution of what is to become of the group of pipeline patents that were
created by the interim Law No. 9,279 in 1996.7 Although there are a
limited number of pipeline patents in existence, much debate has taken
*Vera L. Suarez received her B.S. in Mechanical Engineering from Oklahoma State
University and recently obtained a J.D. at SMU Dedman School of Law in De-
cember 2011.
1. See Lei No. 9.279, de 14 de Maio de 1996, DiAmo OICIAL DA UNIAo [D.O.U.] de
15.05.1996 (Brazil.), translation available at http://www.wipo.int/wipolex/en/
text.jsp?fileid=125397 [hereinafter Law No. 9,279].
2. S.T.J., Ap. No. 731.101 - RJ (2005/0036985-3), Relator: Joio Otavio de Noronha,
28.4.2010, 219, DiAm~no DO JunICIAno Ei nIRONI(o [D.J.e.], 19.05.2010, 252
(Braz.) [hereinafter Nat'l Inst. of Indus. Prop. v. Pfizer Ltd.].
3. Hector Chagoya & Sergio De Alva, Mexico: Using Pipeline Patents to Protect
Pharmaceuticals, MANAGING INTiLu. PRo'. (Mar. 1, 2003), http://www.manag-
ingip.com/Article/1321760/Channel/194878/Mexico-Using-pipeline-patents-to-pro-
tect-pharmaceuticals.html?Articleld= 132 1760 &p=2.
4. Nat'1 Inst. of Indus. Prop. v. Pfizer Ltd., supra note 2, at 4.
5. Claudia Jurberg, Brazilian Generic Drug Registration Sets Standard for 'Pipeline'
Patents, INTLL. PROP. WATi (May 13, 2010), http://www.ip-watch.org/weblog/
2010/05/1 3/brazilian-generic-drug-registration-sets-standard-for-pipel ine-patents/.
6. See id.
7. Nat'l Inst. of Indus. Prop. v. Pfizer Ltd., supra note 2, at 5; Ed Taylor, Viagra's
Brazilian Patent Expires in June, Nation's Highest Court Rules, 24 WoiD.o INTIA.L
Pio'. Riw. 006 D3 (BNA) (Jun. 1, 2010).
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place in Brazil regarding the constitutionality of Law No. 9,279 and its
effects, which are argued to limit the accessibility of generic drugs to the
Brazilian population.8 While Pfizer did not evaluate the constitutionality
of Law No. 9,279, it did provide a final resolution regarding how long the
patents will remain in effect, and this ruling might violate the Agreement
on Trade Related Aspects of Intellectual Property (TRIPS). 9 The first
section will outline the development of patent protection for pharmaceu-
tical products in Brazil. The second section will provide a brief history of
how Pfizer Ltd. (Pfizer) obtained patent protection for the Viagra tech-
nology. The third section will detail how the Viagra patent was initially
challenged in Brazilian courts. Finally, the Superior Court's Pfizer deci-
sion and its effects will be compared to governing treaties.
I. DEVELOPMENT OF PATENT PROTECTION FOR
PHARMACEUTICAL PRODUCTS IN BRAZIL
The patent laws of Brazil, in effect from 1971 to 1997, did not protect
pharmaceutical products or processes. 0 The copying or piracy of
pharmaceuticals was so common and widespread in Brazil, that the
United States implemented a "Special 301" sanction against Brazil in
1987." This sanction resulted in "a 100% tariff on $39 million dollars
worth of Brazilian imports to the United States."' 2 While this sanction
did negatively affect Brazil, in that it virtually prohibited Brazilian ex-
ports of "certain paper products, non-benzenoid drugs, and consumer
electronic items" from entering the American market during 1989 and
1990,13 it took the creation of TRIPS to force Brazil into pharmaceutical
patent protection compliance.14
One of the main purposes of creating TRIPS, which came into effect on
January 1, 1995, was to force Brazil, China, and India into providing a
minimal standard of intellectual property protection.' 5 Pharmaceutical
companies, which were unable to control the copying of pharmaceuticals,
8. Tahir Amin, Brazil's Attorney General Challenges Constitutionality of "Pipeline"
Protection in Patent Law, 1-MAK Dor ORG, (May 11, 2009), http://www.i-
mak.org/i-mak-blog-updates/2009/5/12/brazils-attorney-general-challenges-consti-
tutionality-of-pip.html; Taylor, supra note 7.
9. See Marrakesh Agreement Establishing the World Trade Organization, Annex IC:
Agreement on Trade-Related Aspects of Intellectual Property Rights, Apr. 15,
1994, 1867 U.N.T.S. 154 [hereinafter TRIPS Agreement]; Nat'l Inst. of Indus.
Prop. v. Pfizer Ltd., supra note 2, at 5.
10. Naomi A. Bass, Note, Implications of the TRIPS Agreement for Developing Coun-
tries: Pharmaceutical Patent Laws in Brazil and South Africa in the 21st Century, 34
GEO. WASH. INT'L L. REv. 191, 206-07 (2002).
11. Id.
12. Id.
13. Bilateral Trade Disputes Involving the United States, Over Intellectual Property and
Health Care, CONSUMER PROJECI ON TECH., Sept. 15, 2000, http://www.cptech.org/
ip/health/country/allcountries.html.
14. Bass, supra note 10, at 207.
15. Christopher S. Mayer, Note & Comment, The Brazilian Pharmaceutical Industry
Goes Walking From Ipanema to Prosperity: Will the New Intellectual Property
Law Spur Domestic Investment?, 12 TEMP. INT'L & COMP. L.J. 377, 380-81 (1998).
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strongly encouraged a requirement for minimal patent standards of phar-
maceutical products in developing countries.16 TRIPS was adopted after
much negotiation and specifically details that pharmaceutical products
and processes should be provided patent protection for a minimum term
of twenty years.' 7 Developed countries were given one year to change
their laws to comply with the protection requirements, while undevel-
oped countries were given five years to comply.18 Brazil implemented
Law No. 9,279 less than two years after the implementation of TRIPS.' 9
A. BRAZIL ENACTS LAW No. 9,279 TO COMPLY WITH TRIPS
In order to comply with TRIPS and to avoid further sanctions, Brazil
passed Law No. 9,279, providing protection to pharmaceutical products
and processes, which took effect on May 16, 1996.20 Law No. 9,279 al-
lowed a Brazilian patent to be granted for pharmaceuticals that already
obtained a patent in another country. 21 Law No. 9,279 details that:
1. the filing of a patent application must occur within one year from
the publication of Law No, 9279 (from May 14, 1996 - May 14,
1997);
2. the patent application will automatically be published and a third
party could submit comments or challenge the application within
ninety days of publication;
3. upon finding that the material was patentable subject matter, and
upon proof that the patent was granted in the country where the
first application was filed, the patent shall be granted in Brazil, just
as it was granted in its country of origin; and
4. the patent granted "will be guaranteed the remainder of the term
of protection in the country where the first application was filed,
counted from the date of filing in Brazil and limited to the term [of
twenty years]." 22
B. THE PARIS CONVENTION DETERMINES THE EFFECTS OF CLAIMING
PRIORITY TO PRIOR APPLICATIONS
Brazil has also been a member of the Paris Convention Agreement
since 1884 and is therefore required to provide protection in accordance
16. Id. at 381.
17. Id.; TRIPS Agreement, supra note 9, at art. 33.
18. TRIPS Agreement, supra note 9, at art. 65.
19. See Law No. 9,279, supra note 1; Mayer, supra note 15, at 380.
20. Adriana Rizzotto, Overview on the Latest Developments on Patent Protection In
Brazil, with focus on Biotechnology, Business Methods and Computer-Implemented
Inventions, INTuL.. PRoP. OWNies Assoc. (Mar. 2009), www.ipo.org/AM/Tem-
plate.cfm?section=Home&Template=/CM/ContentDisplay.cfm&Con tent D=
21973.
21. Law No. 9,279, supra note 1, arts. 230-31.
22. Id.
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with the Paris Convention. 2 3 The Paris Convention specifically states,
"patents obtained with the benefit of priority shall, in the various coun-
tries of the Union, have duration equal to that which they would have,
had they been applied for or granted without the benefit of priority."2 4
This suggests that the patent term is not calculated from the priority date,
because the duration should be the same regardless of whether the bene-
fit of priority was claimed. When interpreting TRIPS in light of the Paris
Convention, it appears that a patent should be granted for a twenty-year
term-starting from the filing date of a patent application that developed
into a patent and not starting from a priority date of a previously filed
and abandoned application.
II. THE EUROPEAN PATENT OFFICE ORIGINALLY GRANTS
PATENT PROTECTION TO THE
VIAGRA TECHNOLOGY
Patent applicants generally should file a patent application as early as
possible to establish a "priority date" corresponding to the filing date,
proving that the applicant invented or filed no later than this date. It is
common for applicants to file a first application to obtain this priority
date and then later abandon it.25 The applicants then use this priority
date in subsequent applications that develop into issued patents. 26 These
patent applications that are filed in accordance with the Patent Coopera-
tion Treaty and reference an earlier priority date generally have a patent
term calculated from the filing date of the later application instead of the
older, priority date27
Pfizer embraced the tactic of claiming priority of an abandoned appli-
cation when obtaining patent protection for the technology related to
Viagra. Viagra consists of an enzyme called phosphodiesterase (PDE5)
and an inhibitor, Sildenafil. 2 8 Therefore, there are two key but separate
components to the drug Viagra. Pfizer first submitted a patent applica-
tion, GB19900013750 ('750 patent), relating to the inhibitor Sildenafil in
the United Kingdom on June 20, 1990.29 This '750 application was later
abandoned and did not develop into an issued patent.30 But, Pfizer used
the '750 patent application as a priority date when later filing patent ap-
23. Paris Convention for the Protection of Industrial Property, Mar. 20, 1883, as last
revised at Stockholm July 14, 1967, 21 U.S.T. 1583, 828 U.N.T.S. 305 [hereinafter
Paris Convention].
24. Id. art. 4bis(5).
25. European Patent Office Guidelines for Examination/Part C, JAPAN PATEPNT OF-
FIciE, http://www.jpo.go.jp/shiryou-e/s sonota-e/fips.e/epo/gec/chap5.htm (last vis-
ited on Oct. 15, 2011).
26. Id.
27. Patent Cooperation Treaty art. 8, June 19, 1970, 28 U.S.T. 7645,1160 U.N.T.S. 231;
Paris Convention, supra note 23.
28. Brazil Accepts British Court Ruling Revoking Patent on Viagra Enzyme, WORLD
INTEL. Pi~op. R Powr (BNA) (Aug. 1, 2007), available at 2007 WL 2110667 .
29. See European Patent No. 0463756(filed June 7, 1991) [hereinafter '756 Patent].
30. Taylor, supra note 7.
VIAGRA RULING
plication, EP 0463756 ('756 patent), in the European Patent Office on
June 7, 1991.31 The '756 application protects Sildenafil Citrate and did
develop into a patent, which issued on April 19, 1995, and is still in force
in the United Kingdom with a maximum expiration date of June 21,
2013.32 Pfizer also received a patent for using Sildenafil Citrate to treat
male impotence, European Patent 702,555 ('555 Patent), which was a sep-
arate patent from the '756 patent that only protected the chemical itself.33
No patent applications relating to the Viagra technology were filed in
Brazil in 1991, because Brazil did not provide patent protection to phar-
maceutical inventions at that time.3 4
After Brazil enacted Law No. 9,279, Pfizer submitted a patent applica-
tion for Viagra's active ingredient, Sildenafil Citrate.3 5 This application
was one of over 1,100 patent applications filed in Brazil at that time and
termed "pipeline patents."36 At the time of application, Pfizer, along
with the other patent applicants, expected to be granted a patent with a
term of twenty years, beginning from the filing date in Brazil, and based
on a literal reading of the 9,279 law.37 The Brazilian Patent Office did
grant Pfizer a patent for Sildenafil Citrate issued as BR 9102560A ('560
patent). 3 8 But, no expiration date was determined at the time of issu-
ance, as is the normal practice.3 9 Therefore, at the time of issue, the pat-
ent term was not expressly determined.40
III. THE VIAGRA PATENT TERM CHALLENGE IN THE
BRAZILIAN COURTS BEGAN BY A PARTIAL
INVALIDATION IN A BRITISH COURT
The '756 patent protecting the active ingredient of Sildenafil Citrate
was challenged in Brazil only after a similar challenge was brought in a
British court. 41 The '555 patent validity was challenged in a British court
31. '756 Patent.
32. '756 Patent; intellectual Prop. Office of the U.K., Supplementary Protection Cer-
tificate Search for '756 Patent, available at http://www.ipo.gov.uk/types/patent/p-
os/p-find/p-find-spc/p-find-spc-bypatentresults.htm?number=ep0463756&submit=
Go+%BB (last visited on Nov. 6, 2011).
33. See European Patent No. 0702555 (filed May 13, 1994); Lilly Icos Ltd. v. Pfizer
Ltd., [2002] EWCA (Civ) 1, [A3/2000/3811], [1] 59 BMLR 123 (Eng.), available at
http://www.bailii.org/ew/cases/EWCA/Civ/2002/1.html.
34. Bass, supra note 10, at 206.
35. See Braz. Patent No. 9102560 (filed June 7, 1991) [hereinafter '560 Patent].
36. Amin, supra note 8.
37. Court Deals Another Setback for Firms Trying to Extend Drug Patents in Brazil,
WoRLo IN TIA. Pizop. Ri:v. (BNA) (Feb. 1, 2010), http://news.bna.com/wiln/dis-
play/batch-print-display.adp?searchid=12579719.
38. '560 Patent.
39. Press Release, Research and Markets, Brazil Pharmaceutical Market Overview,
(Sept. 10, 2010), http://www.forbes.com/feeds/businesswire/2010/09/10/business-
wirel45139986.html.
40. Id.
41. See Lilly Icos LLC,[2002] EWCA (Civ) 1, No. A3/2000/3811 [1]; Pfizer Loses
Viagra Patent, BBC (Nov. 8, 2000), http://news.bbc.co.uk/2/hi/business/
1013244.stm; Brazil Accepts British Court Ruling Revoking Patent on Viagra En-
zyme, supra note 28.
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by a Pfizer competitor. 42 The British court found that the technology was
obvious and that the '555 patent was invalid.4 3
Bayer, which produces a similar product to Viagra, used this British
court ruling to challenge Pfizer's Brazilian Viagra '560 patent and re-
quested it be invalidated in Brazil. 4 4 Bayer argued that, based on Law
No. 9,279, if the '555 patent was invalidated in the country of origin, then
the Brazilian patent office should respect the British ruling and invali-
date the '560 patent, because the term of a pipeline patent in Brazil was
only guaranteed for the remainder of the term in the country of origin. 45
Although Bayer and Pfizer settled this dispute, the National Institute of
Industrial Property (INPI), a government entity that processes and grants
patents, continued to pursue Bayer's objections.46
A. INPI ASSERTS THE PATENT TERM SHOULD BE CALCULATED FROM
THE PRIORITY DATE AND NOT THE INTERNATIONAL FILING DATE
The INPI attacked the validity of all pipeline patents in multiple ways,
but the critical issue in Pfizer relates to the term of protection for pipeline
patents in Brazil.4 7 Pharmaceutical companies will lose hundreds of mil-
lions of dollars if patent protection is lost, because generic drugs will be
able to enter the market and offer significantly reduced prices for similar
drugs. 4 8 Generic pharmaceutical companies will reap the benefits of a
shorter protection term for patented medicines, and the medicines will
become more readily available to the Brazilian population. 49
The pharmaceutical companies wanted the longest patent term possible
and therefore argued that Law No. 9,279 should be read to allow for a
twenty-year term from the date of filing in Brazil.50 Because all pipeline
patents had filing dates between May 1996 and May 1997, they should
expire between May 2016 and 2017.51 Alternatively, the pharmaceutical
companies argued that the twenty-year term should begin from the date
of international filing instead of the priority date.52 Additionally, phar-
maceutical companies asserted that if an extension of a patent term was
granted in the country of original filing for the primary patent, the corre-
sponding Brazilian pipeline patent term should also be extended.53 Fi-
42. Lilly Icos LLC, [2002] EWCA (Civ) 1 No. A3/2000/3811, [2].
43. Id.




47. Nat'l Inst. of Indus. Prop. v. Pfizer, supra note 2, at 3; Amin, supra note 8.
48. See Amin, supra note 8; Brazil Accepts British Court Ruling Revoking Patent on
Viagra Enzyme, supra note 28.
49. Clark A.D. Wilson, The TRIPS Agreement: Is It Beneficial to the Developing
World, or Simply a Tool Used to Protect Pharmaceutical Profits for Developed
World Manufacturers?, 10 J. Ticii. L. & Poi-'y 243, 256 (2005).
50. Taylor, supra note 7.
51. See id.
52. See id.
53. Jurberg, supra note 5.
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nally, the pharmaceutical companies looked to international treaties, such
as TRIPS and the Paris Convention, and argued that patent terms should
not be shorter than twenty years. 54
The INPI and generic pharmaceutical drug companies desire the short-
est patent terms possible and ultimately prefer that all patent pipelines be
invalidated.5 5 For this reason, the INPI argued that any filing of a patent
application, including one that is abandoned and is only used as a priority
date, should mark the beginning of the twenty-year protection.56 Be-
cause Pfizer submitted an initial application in the United Kingdom on
June 21, 1990, the INPI argued that the Brazilian Viagra patent should
expire on June 21, 2010, which is twenty years after the priority date.5 7
B. LOWER BRAZILIAN COURTs RULED IN FAVOR OF THE LATER
EXPIRATION DATE
Two lower Brazilian courts evaluated Law No. 9,279 and interpreted it
as allowing for Pfizer's patent term to extend until June 7, 2011, meaning
the international filing date should be used to calculate pipeline patent
terms and not the priority date.58 The lower court focused on the literal
wording of Law No. 9,279 art. 230, § 4 and held that a pipeline patent's
period of protection continues throughout the term remaining in the
country in which the first application was filed.59 Because the patent that
was granted in the United Kingdom involving the Viagra technology was
still protected, protection should still be present in Brazil. 60 The lower
court also stated that it is not the Brazilian Patent Office's responsibility
to review the acts of foreign patent offices, and the office should not eval-
uate the adequacy of those patent offices' patent extensions. 6 1
IV. THE SUPERIOR JUSTICE COURT INTERPRETS TRIPS
AND THE PARIS CONVENTION IN PFIZER
The INPI appealed the lower court's decision to the Superior Justice
Court, which is one of the highest courts in Brazil.62 The Superior Justice
Court released its decision on April 28, 2010, less than two months before
the contested expiration date of the '560 patent. 63 The Pfizer Court
noted that the patent pipeline system, or Law No. 9,279, was imple-
54. See Nat'l Inst. of Indus. Prop. v. Pfizer, supra note 2, at 9.
55. Id.
56. Id.
57. See id.; see also Taylor, supra note 7.
58. See TRF-2, No. 2001.02.01.045636-3, Relator: Sergio Schwaitzer, 03.03.2004, Didrio
da Justiga da Uniio [D.J.u.], 17.03.2004, 212, 212-13 (Braz.); see also Nat'I Inst. of
Indus. Prop. v. Pfizer, supra note 2, at 6-8 (discussing the decisions of lower Brazil-
ian courts).
59. TRF-2, No. 2001.02.01.045636-3, Relator: Sergio Schwaitzer, 03.03.2004, Dibrio da
Justiga da Uniio [D.J.u.], 17.03.2004, 212, 212-13 (Braz.).
60. See id.
61. Id.
62. See Nat'l Inst. of Indus. Prop. v. Pfizer, supra note 2, at 1.
63. Id.
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mented for a temporary time and provided an exception to the patent
system; therefore, it must be strictly interpreted. 64
The Pfizer Court interpreted Law No. 9,279 in light of Article 33 of
TRIPS to conclude that the term of patent protection will begin from the
date of first deposit, regardless of whether this system was not the system
of original grant.65 The date of first deposit for the '560 patent was June
20, 1990.66 Focus was given to the wording of TRIPS's Article 33 foot-
note, which states that "[i]t is understood that those Members which do
not have a system of original grant may provide that the term of protec-
tion shall be computed from the filing date in the system of original
grant. "67
The Pfizer Court reasoned that because Brazil did not have a system of
original grant for pharmaceutical patent applications, the filing date in
the system of the original grant begins with the very initial deposit or first
application, regardless of whether the system receiving the first applica-
tion was the first to grant protection. 68 This analysis ignores the reality
that the United Kingdom patent system was not the system of original
grant, because the patent application that was filed in this system was
abandoned. Instead, the European Patent Office was the patent system
that originally granted a patent.69 This European Patent system lists a
filing date of June 7, 1991.70
To satisfy the twenty-year term minimum requirement, the Pfizer
Court stated that at least some form of patent protection begins at the
time of first deposit, which is the priority date.71 The Pfizer Court be-
lieved that protection stemming from a priority date involves the ability
to request other countries to accept the priority date.72 The Pfizer Court
also reasoned that during this twelve-month period, the applicant has cer-
tain safeguards such as the preservation of characteristic novelty of the
invention and the inability of third parties to make use of or patent the
invention in other countries.73 But patent protection, or the ability to
prevent others from using, making, and selling the patented invention,
only begins when the patent is issued.74 The Pfizer Court stated that
safeguards continue regardless of whether the applicant later withdraws
or abandons the patent application.75 But the establishment of a priority
date is often viewed as merely a method of "alleviating the negative con-
64. Id. at 8.
65. Id. at 9.
66. '560 Patent.
67. Nat'1 Inst. of Indus. Prop. v. Pfizer, supra note 2, at 9 (quoting TRIPS Agreement,




71. Nat'l Inst. of Indus. Prop. v. Pfizer, supra note 2, at 22, 26.
72. Id.
73. Id.
74. See e.g., 35 U.S.C. § 154 (2006).
75. Nat'l Inst. of Indus. Prop. v. Pfizer, supra note 2, at 10.
VIAGRA RULING
sequences of the principle of territoriality in patent law"-while the in-
ventor is trying to establish international protection for his invention. 76
The Pfizer Court reasoned that the initial deposit or priority date begins
the term of patent protection, regardless of its later abandonment and
regardless of no patent rights stemming from the priority date.77 There-
fore, it believes that the twenty-year minimum term of TRIPS is
satisfied.78
A. THE PFIZER COURT RULING APPEARS TO BE INCONSISTENT WITH
PATENT TERMS UNDER THE PARIS CONVENTION AND WILL
HAVE WIDESPREAD NEGATIVE EFFECTS
Generally, the method of obtaining a priority date by filing an initial
application in one country's patent system, abandoning the initial applica-
tion, and then using the priority date for future international patent appli-
cations is a common practice.79 When this occurs, twenty years of
protection is calculated from the international filing date, and not the pri-
ority date.80 The Paris Convention specifically states that "patents ob-
tained with the benefit of priority shall, in the various countries of the
Union, have a duration equal to that which they would have, had they
been applied for or granted without the benefit of priority."81 The Pfizer
Court holding that the priority date, instead of the filing date, starts the
twenty-year patent term seems to contradict a clear reading of the Paris
Convention and TRIPS.
The Pfizer holding sets a confusing precedent for patent pipeline cases
and patent term adjustments. 8 2 The INPI was confident that this holding
would accelerate the expiration of pipeline patents by one or two years.83
In June 2010, there were more than 100 similar cases before Brazilian
courts involving the validity and the expiration dates of pipeline patents
relating to pharmaceutical products or processes. 84 Since the Pfizer deci-
sion, multiple other pipeline patents have been truncated in a similar
manner.85 Brazilian courts truncated the patent terms for Lipitor, a
medicine that controls cholesterol, and Gleevec, a medicine used for can-
76. Case T-0015/01, Mystery Swine Disease/SDLO, [2004] O.J.E.P.O. 34 (Technical
Bd. Appeal 3.3.4, June 17, 2004), available at http://www.epo.org/law-practice/case-
law-appeals/pdf/t0l0015ex1.pdf.
77. Nat'l Inst. of Indus. Prop. v. Pfizer, supra note 2, at 10.
78. Id.
79. See European Patent Office Guidelines for Examination Part C, supra note 25, at
§§ 2.1-2.2.
80. Paris Convention, supra note 23, at art. 4bis(5).
81. Id.
82. Jurberg, supra note 5.
83. Id.
84. Taylor, supra note 7.
85. See Patricia Covarrubia, INPI Did It Again - Pipeline Mechanism, IP TANao (July
12, 2011, 11:23 AM), http://iptango.blogspot.com/2011/07/inpi-did-it-again-pipe-
line-mechanism.html [hereinafter Covarrubia, INPI Did It Again]; Guna, Brazil
Pipeline Patents - Term Extention, PAriNT DAILY (IARMA) (Nov. 2, 2011), http:/
/patentdaily.wordpress.com/2011/02/11 /brazil-pipeline-patents-term-extension/.
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cer treatments.86 Also, patent terms were shortened for patents protect-
ing medications for Parkinson's disease, blood clots prevention, and
cardiac arrhythmias.87
In response to losing patent protection in Brazil, Pfizer acquired a forty
percent interest in Teuto, a Brazilian generic drug manufacturing com-
pany, which allowed Pfizer "to increase its participation in Brazil's phar-
maceutical market."88 It is unknown whether other pharmaceutical
companies owning patents soon to expire will follow suit.
86. Jos6 Carlos Vaz e Dias, INPI Wins the Battle Against the Patent Extension for Lip-
itor, IP TANGO (Aug. 30,2010,4:25 AM), http://iptango.blogspot.com/2010/08/inpi-
wins-battle-against-patent.html; Patricia Covarrubia, Brazilian Pipeline System -
Again, IP TANGO (Oct. 25, 2010, 6:00 AM), http://iptango.blogspot.com/2010/10/
brazilian-pipeline-system-again.html.
87. Covarrubia, INPI Did It Again, supra note 84; Guna, supra note 84.
88. Agence France-Presse, Pfizer Buys into Brazilian Drug Maker Teuto, INDUsTRY
WEEK (Oct. 20, 2010), http://www.industryweek.com/articles/pfizer-buys-intobra-
zilian-drug-maker teuto 23066.aspx.
